The healthcare sector is rapidly going through a transition phase, with Internet of Medical Things devices revolutionising health IT infrastructure such as electronic health records (EHR) and big data analytics...
6 October 2017
4 October 2017
Osteoarthritis (OA) is one the developed world’s most common diseases, with over 80% of the senior population suffering from knee or hip OA.
2 October 2017
The past 15 years have witnessed an explosion in the drugs market for multiple sclerosis (MS), enabling the first disease modifying therapies in the neurodegenerative disease market to become a...
29 September 2017
Artificial intelligence (AI) is being implemented in almost every aspect of day-to-day life. From recommendations on Netflix or Spotify and fraud detection for your bank account, to experimental self-driving cars,...
28 September 2017
This month, Merck’s Mavenclad (cladribine) become available in the UK to treat highly active relapsing multiple sclerosis (MS). Mavenclad is the first high efficacy, infrequent dosing oral agent approved for...
30 August 2017
While covering an expansive number of cardiovascular (CV) indications, this year’s European Society of Cardiology (ESC) Conference in Barcelona had a particular focus on digital health.
24 August 2017
Following a move to fix price ceilings for coronary stent products, India’s National Pharmaceutical Pricing Authority (NPPA) has announced a plan to cap the pricing of orthopedic knee replacement implants.
22 August 2017
In July 2017, Pentax Medical and Shanghai AoHua Photoelectricity formed a joint venture (JV) company to develop products in the field of flexible medical endoscopy.
25 July 2017
In December 2016, the 21st Century Cures Act was signed into law, $6.3bn in funding was directed towards research and drug development, and increased access to treatments for patients with...
3 July 2017
The ability to edit the human genome has been eagerly anticipated for many years. While the possibilities are exciting for many, there are serious ethical concerns that are already beginning...